Swiss HIV prevention policy for intravenous drug users is a model for success

May 25, 2018, University of Zurich
HIV infecting a human cell. Credit: NIH

Switzerland's pragmatic HIV prevention policy for intravenous drug users has been extremely successful. Thousands of HIV infections and AIDS cases have been prevented thanks to harm reduction measures, as shown by an analysis by the University of Zurich, the University Hospital Zurich and the Swiss HIV Cohort Study.

Researchers at the University of Zurich, the University Hospital Zurich were able to document and quantify the success of measures taken for the of HIV transmission through intravenous use in Switzerland, based on a mathematical model and detailed clinical, viral genetics and epidemiological data from the Swiss HIV Cohort Study. Harm reduction measures such as needle exchanges, methadone programs, supervised heroin programs and contact and consultation services for drug users were all analyzed. Marzel and his colleagues could demonstrate through their work that the measures in Switzerland had prevented a total of over 15,000 HIV infections among drug users. "Previously, the HIV epidemic frequently spilled over from intravenous drug users to the general population through sexual contact, meaning that the prevention measures in drug users also indirectly prevented more than 2,500 cases of HIV in people who do not use intravenous drugs," says Prof. Roger Kouyos, head of the study, which was recently published in the journal Open Forum Infectious Diseases.

Impact on public health

Marzel et al's evaluation not only documents the success of Switzerland's pragmatic prevention policy, but also demonstrates that the harm reduction and prevention measures protect the general population from HIV infections. The analysis also demonstrates the value of the Swiss HIV Cohort Study. "Without the data from the cohort study, which began its work 30 years ago, it would not have been possible to produce such a detailed quantitative analysis," says Prof. Kouyos.

Even without a detailed cost analysis, the economic implications are clear: based on a conservative estimate for the annual cost of treatment of CHF 20,000 per infection, the Swiss healthcare system would have spent an additional CHF 340 million per year on the 17,000 prevented infections. These estimates thus indicate that prevention measures have saved over CHF 3.4 billion in treatment costs over the last 10 years. The results of the data analysis demonstrate the outstanding effectiveness of the implemented harm reduction and prevention measures. Unfortunately, these are still considered controversial abroad, especially in Eastern Europe. In many countries, no prevention measures are offered at all. "Many cases of the transmission of HIV through intravenous drug use could have probably been avoided by implementing the prevention measures. Considering that worldwide 1.7 million users are HIV positive and around 30% of new infections outside Sub-Saharan Africa occur in this risk group, this is another noteworthy result of our research project," says Dr. Alex Marzel of the Institute of Medical Virology, first author of the paper.

The Swiss HIV Cohort Study was founded over 30 years ago, and has collected anonymous data from over 20,000 HIV positive individuals and a biobank containing over 1.5 million blood samples. All university hospitals in Switzerland, as well as many cantonal hospitals and specialized domestic practitioners, contribute to the cohort study. The largest center is located in Zurich.

Explore further: First month after infection is key time to tackle drug-related HIV spread

More information: Alex Marzel et al. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infectious Diseases, Volume 5, Issue 5, 1 May 2018, Doi: 10/1093/ofid/ofy078

Related Stories

First month after infection is key time to tackle drug-related HIV spread

November 8, 2016
Data from the mid-1990s AIDS epidemic in Russia and Ukraine shows that the first month after infection is the key period to control the spread of the virus in drug-using populations, according to a new study by researchers ...

Gastrointestinal illnesses cost the Swiss health care sector up to EUR 45 million per year

August 12, 2016
In Switzerland, between 300,000 and 700,000 patients per year visit a doctor due to acute diarrhoea. Until now, the financial burden on the Swiss health care system had been completely unclear. The study, recently published ...

Cluster of resistant tuberculosis pathogen discovered

January 9, 2018
Between February and November 2016, the Institute of Medical Microbiology at the University of Zurich discovered a multidrug-resistant Mycobacterium tuberculosis in eight refugees arriving in Europe from the Horn of Africa. ...

Untreated HIV carriers transmit resistant viruses

November 18, 2013
Around one in every ten newly infected HIV carriers in Switzerland has viruses that are resistant to at least one of the three classes of drugs used to treat AIDS. Contrary to previously held assumptions, resistant viruses ...

Avahan AIDS initiative may have prevented 600,000 HIV infections in India over 10 years

September 29, 2013
A programme funded by the Bill & Melinda Gates Foundation may have saved around 600,000 people in India from becoming infected with HIV over the course of a decade, according to a new report.

Recommended for you

New HIV therapy reduces virus, boosts immunity in drug-resistant patients

August 15, 2018
In a study, a new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy ...

In choosing care, HIV patients in Zambia prefer kindness over convenience

August 15, 2018
As a healthcare patient, what would you sacrifice for a provider with a nice—rather than rude—attitude? For HIV patients in Zambia, the answer may surprise you.

Details of HIV-1 structure open door for potential therapies

August 9, 2018
New research provides details of how the structure of the HIV-1 virus is assembled, findings that offer potential new targets for treatment.

Researchers uncover potential new drug targets in the fight against HIV

August 7, 2018
Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV—the virus that ...

Naltrexone helps HIV positive individuals reduce heavy alcohol use

August 7, 2018
Extended-release naltrexone—an injection that decreases heavy drinking in the general population when taken in conjunction with counseling—appears to help HIV-positive individuals reduce their number of heavy drinking ...

EU door opens for generic version of AIDS medicine Truvada

July 26, 2018
Patient associations on Thursday lauded an EU decision to allow the sale of generic versions of Truvada, an anti-retroviral medicine used by those diagnosed HIV-positive, the virus causing AIDS.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.